View Item 

Show simple item record

The effect of Daclizumab in a high-risk renal transplant population
dc.contributor.authorMeier-Kriesche, Herwig-Ulfen_US
dc.contributor.authorKaza, Harshaen_US
dc.contributor.authorPalekar, Sadanand S.en_US
dc.contributor.authorFriedman, Gary S.en_US
dc.contributor.authorMulgaonkar, Shamkant P.en_US
dc.contributor.authorOjo, Akinlolu O.en_US
dc.contributor.authorKaplan, Bruceen_US
dc.date.accessioned2010-06-01T22:17:05Z
dc.date.available2010-06-01T22:17:05Z
dc.date.issued2000-10en_US
dc.identifier.citationMeier-Kriesche, Herwig-Ulf; Kaza, Harsha; Palekar, Sadanand S; Friedman, Gary S; Mulgaonkar, Shamkant P; Ojo, Akinlolu O; Kaplan, Bruce (2000). "The effect of Daclizumab in a high-risk renal transplant population." Clinical Transplantation 14(5): 509-513. <http://hdl.handle.net/2027.42/75298>en_US
dc.identifier.issn0902-0063en_US
dc.identifier.issn1399-0012en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/75298
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=11048998&dopt=citationen_US
dc.format.extent98482 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherMunksgaard International Publishersen_US
dc.publisherBlackwell Publishing Ltden_US
dc.rightsMunksgaard 2000en_US
dc.subject.otherAfrican Americanen_US
dc.subject.otherDaclizumaben_US
dc.subject.otherHigh Risken_US
dc.subject.otherHispanicen_US
dc.subject.otherImmunosuppressionen_US
dc.subject.otherInductionen_US
dc.subject.otherKidney Transplantationen_US
dc.titleThe effect of Daclizumab in a high-risk renal transplant populationen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelMedicine (General)en_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI,en_US
dc.contributor.affiliationotherDepartment of Transplantation, Saint Barnabas Medical Center, Livingston, NJ,en_US
dc.contributor.affiliationotherDepartment of Transplantation, Newark Beth Israel Medical Center, 201 Lyons Avenue, Newark, NJ, USAen_US
dc.identifier.pmid11048998en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/75298/1/j.1399-0012.2000.140511.x.pdf
dc.identifier.doi10.1034/j.1399-0012.2000.140511.xen_US
dc.identifier.sourceClinical Transplantationen_US
dc.identifier.citedreferenceBleyer AJ, Tell GS, Evans GW, Ettinger WHJ & Burkart JM. Survival of patients undergoing renal replacement therapy in one center with special emphasis on racial differences. Am J Kidney Dis 1996: 28: 72.en_US
dc.identifier.citedreference2 Katznelson S, Gjertson DW, Cecka JM. The effect of race and ethnicity on kidney allograft outcome. Clin Transplant 1995: 379.en_US
dc.identifier.citedreferenceVasquez EM, Benedetti E & Pollak R. Late acute rejection is more prevalent among African-American renal allograft recipients and is frequently associated with allograft loss. Transplant Proc 1998: 30: 1173.en_US
dc.identifier.citedreference4 The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996: 61: 1029.en_US
dc.identifier.citedreferenceKahan BD, Julian BA, Pescovitz MD, Vanrenterghem Y & Neylan J Rapamune Study Group,. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Transplantation 1999: 68: 1526.en_US
dc.identifier.citedreferenceLaskow DA, Vincenti F, Neylan JF, Mendez R & Matas AJ. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. Transplantation 1996: 62: 900.en_US
dc.identifier.citedreferenceNeylan JF US Renal Transplant Mycophenolate Mofetil Study Group,. Immunosuppressive therapy in high-risk transplant patients: dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. Transplantation 1997: 64: 1277.en_US
dc.identifier.citedreferenceNeylan JF FK506 Kidney Transplant Study Group,. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. Transplantation 1998: 65: 515.en_US
dc.identifier.citedreferenceNeylan JF FK506 Kidney Transplant Study Group,. Effect of race and immunosuppression in renal transplantation: three-year survival results from a US multicenter, randomized trial. Transplant Proc 1998: 30: 1355.en_US
dc.identifier.citedreferenceSchweitzer EJ, Yoon S, Fink J, Wiland A, Anderson L, Kuo PC, Lim JW, Johnson LB, Farney AC, Weir MR & Bartlett ST. Mycophenolate mofetil reduces the risk of acute rejection less in African American than in Caucasian kidney recipients. Transplantation 1998: 65: 242.en_US
dc.identifier.citedreferenceHariharan S, Alexander JW, Schroeder TJ & First MR. Outcome of cadaveric renal transplantation by induction treatment in the cyclosporine era. Clin Transplant 1996: 10: 186.en_US
dc.identifier.citedreferenceLight JA, Kelly JL, Aquino A, Neu L, DeNavas L & Williams K. Improving renal transplant outcomes in African Americans with OKT3 induction therapy. Transplant Proc 1993: 25: 2436.en_US
dc.identifier.citedreferenceSzczech LA, Berlin JA & Feldman HI Anti-Lymphocyte Antibody Induction Therapy Study Group,. The effect of antilymphocyte induction therapy on renal allograft survival. A meta-analysis of individual patient-level data. Ann Intern Med 1998: 128: 817.en_US
dc.identifier.citedreferenceVincenti F, Laskow DA, Neylan JF, Mendez R & Matas AJ. One-year follow-up of an open-label trial of FK506 for primary kidney transplantation. A report of the U.S. Multicenter FK506 Kidney Transplant Group. Transplantation 1996: 61: 1576.en_US
dc.identifier.citedreferenceVincenti F, Lantz M, Birnbaum J, Garovoy M, Mould D, Hakimi J, Nieforth K & Light S. A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation. Transplantation 1997: 63: 33.en_US
dc.identifier.citedreferenceVincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P, Neylan J, Wilkinson A, Ekberg H, Gaston R, Backman L & Burdick J Daclizumab Triple Therapy Study Group,. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998: 338: 161.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1399-0012.2000.140511.x.pdf
Size:
96.17KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.